IIM
HRMY icon

Illumine Investment Management’s Harmony Biosciences HRMY Stock Holding History

Illumine Investment Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,277
Closed -$766K – 67
2026
Q1 		$680K Buy
24,277
+1,032
+4% +$33.8K 0.52% 68
2025
Q4 		$870K Buy
23,245
+878
+4% +$28.9K 0.63% 53
2025
Q3 		$616K Buy
22,367
+976
+5% +$33.6K 0.44% 69
2025
Q2 		$676K Buy
+21,391
New +$688K 0.54% 61

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Illumine Investment Management's HRMY Position: Q2 2026 in Review

Illumine Investment Management sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 24,277 shares — an estimated $766K sold.

Illumine Investment Management first reported a position in HRMY in Q2 2025 and held it in 4 quarters. The position peaked at $870K in Q4 2025. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Illumine Investment Management reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
  • Illumine Investment Management sold 24,277 Harmony Biosciences shares in Q2 2026, an estimated $766K.
  • Illumine Investment Management first reported a position in Harmony Biosciences in Q2 2025 and held it in 4 quarters.
  • Illumine Investment Management's Harmony Biosciences position peaked at $870K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Illumine Investment Management's 13F filing for Q2 2026, filed 29 Jul 2026.